The Mini-Fellowship › Method and science › Precision medicine

Precision medicine in ketamine therapy

Two patients given the same milligrams per kilogram do not end up in the same place. Some of the reasons are well described and worth acting on. Others are claimed more often than they are demonstrated. This page separates the two, because a clinician who cannot tell them apart will either ignore a real interaction or promise a patient something the evidence does not support.

The course director teaching at the whiteboard during a didactic session
Taught inModules 6 and 9
Applied inCase work, Days 3 and 4
ToolClinical Companion interaction checks
References15, all verified
Genotype-guided dosingNot established
StatusPsychiatric use is off-label

For KAP practitioners. How you dose the session matters. Intramuscular: the dose rises to a peak and falls away, so the patient is workable only on either side of it. Concentration-targeted infusion: the patient is brought into the anxiolytic–empathogenic range and held there for the length of the session, with defenses lowered, calm enough to stay with difficult material and present enough to talk about it. One continuous working session, reproducible from visit to visit. See the two curves →

The term itself

What “precision medicine” honestly means here.

The phrase has been used loosely enough in this field that it is worth setting out what it means on this page, and what it does not.

It does not mean a genetic test that produces a dose. No such test exists for ketamine. It does not mean a proprietary algorithm, and it is not a product.

It means taking the whole patient as the input, not just their weight: how they metabolize the drug, their hormonal and nutritional status, their genetics where a report exists, their other medications, the indication, and what they want from treatment and can tolerate.

The plan is built around what you find, written down before the infusion and adjusted as the course goes on. The skill is knowing which findings should change it and which only warrant closer watching — and being able to say, out loud, which is which.

What this page does not claim

Three things you will not find here, because the evidence does not support them.

1

That a genetic test can set a ketamine dose.

2

That height, build or body composition predicts the plasma concentration a patient will reach.

3

That any of this makes ketamine therapy more effective. It makes it more deliberate, which is a different claim.

Learning objectives

On completing this material, participants should be able to:

  1. Describe the metabolic pathway of ketamine and name the enzymes that carry each step.
  2. Distinguish a mechanism demonstrated in vitro from one demonstrated in patients, and say which applies to CYP2B6 genotype.
  3. Take a medication history that finds the interactions that matter, and explain why route changes their size.
  4. Explain why a pharmacogenomic result is treated as one input among several rather than a dosing instruction.
  5. State plainly, to a patient or a colleague, what is known and what is not known about individualizing a ketamine dose.

The pathway

Where the drug goes, and what it becomes.

Ketamine

Given intravenously, ketamine reaches the circulation without passing through the liver first. Given by mouth, most of a dose is metabolized before it ever gets there, which is why oral exposure is both lower and far more variable.

Norketamine

The first and largest step is N-demethylation to norketamine, carried out mainly by CYP3A4 and CYP2B6, with a smaller contribution from CYP2C9.1 Norketamine is not inert: it contributes measurably to analgesia and to cognitive effects.11

Hydroxynorketamines

Norketamine is hydroxylated onward. One of these metabolites, (2R,6R)-hydroxynorketamine, produced antidepressant-like effects in rodents without NMDA-receptor blockade13 — a finding that reshaped the research agenda but has not been established as the mechanism in people.

What reaches the brain

What the patient experiences is the sum of the parent drug and its active metabolites, in proportions that differ between individuals and between routes. The dose on the chart describes none of this.

How the concentration is targeted →

Genotype

A real mechanism, and a claim that outruns it.

CYP2B6 is the part of this subject most likely to be oversold, so the course teaches it in the order the evidence arrived.

In vitro

What is shown in vitro

In human liver microsomes and expressed-enzyme systems, the CYP2B6*6 variant substantially slows N-demethylation of both ketamine enantiomers.2 Later work extended this across a wider range of CYP2B6 variants and cytochrome P450 oxidoreductase.3 The mechanism is not in doubt.

In patients

What was not shown in patients

When the same question was put to people — a single low oral dose, genotyped participants — CYP2B6 genotype did not significantly affect ketamine metabolism or clearance in vivo.4 This is a negative result from one study design, not a refutation of the enzymology, but it is what the human evidence currently says.

In practice

What follows for practice

A CYP2B6 result is not a dosing instruction. It is a reason to pay closer attention: to expect more variability, to watch the infusion more carefully, and to record what happened. It belongs in the chart alongside the medication list, not in a formula.

In the course

What the course teaches

How to read a pharmacogenomic report, what each finding does and does not license, when testing is worth ordering in a complicated case, and how to explain the difference to a patient who arrives holding one.

Interactions

The ones that have actually been measured.

Each of the following was studied in healthy volunteers with S-ketamine. Read the route carefully: oral ketamine passes through the liver before it reaches the circulation, so an interaction that transforms oral exposure may barely move an intravenous infusion.

Drug and mechanismWhat was found
ClarithromycinStrong CYP3A inhibitorGreatly increased exposure to oral S-ketamine.5 Studied orally; expect a smaller effect intravenously.
TiclopidineCYP2B6 inhibitorGreatly increased exposure to oral S-ketamine, and prolonged it.6
ItraconazoleStrong CYP3A inhibitorNo significant effect on oral S-ketamine in the same study6 — a reminder that inhibitor class does not predict the result.
Grapefruit juiceIntestinal CYP3A inhibitorIncreased oral S-ketamine exposure substantially.7 Relevant to oral and sublingual use; not to intravenous.
RifampicinStrong CYP3A and CYP2B6 inducerProfound reduction in exposure to oral S-ketamine, and a smaller reduction intravenously.8 The clearest demonstration that route changes the size of an interaction.
The practical lesson is the itraconazole result. A strong CYP3A inhibitor that did not move ketamine exposure, in the same study in which a CYP2B6 inhibitor did. Interaction risk has to be looked up, not deduced from drug class.

Sex

One human finding, and its limits.

The finding

In the human arm of a 2022 study, plasma ketamine and norketamine concentrations after 0.5 mg/kg intravenously were higher in men than in women; hydroxynorketamine concentrations did not differ by sex.10

The direction surprises people

The common assumption runs the other way. It is worth knowing before a clinician reasons from intuition at the bedside.

The limits

One study, thirty-four patients and twenty-three controls. The mechanistic work behind it was done in mice. It is not a basis for dosing men and women differently, and the course does not teach it as one.

What cannot be predicted

The most useful thing to know is a negative.

The pooled evidence

A systematic review, meta-analysis and population analysis of eighteen pharmacokinetic studies found no covariate that improved the model: not age, not sex, not any measured patient characteristic.9 Volume of distribution averaged about 252 liters per 70 kg and clearance about 79 liters per hour.

What that does not mean

It does not mean every patient reaches the same concentration. Variability between individuals is large. It means the variability is not currently explained by anything you can measure in the office beforehand.

What that does mean

A formula will not get you to a target. The plan has to be made against a model, and then checked against the patient in the chair. This is the whole argument for monitoring closely and adjusting.

In practice

What a graduate actually does with this.

In the medication review

Every applicant learns a structured medication review that looks specifically for CYP3A and CYP2B6 inducers and inhibitors, and for the route-dependence that decides whether any of it matters.

In setting the target

Where an interaction is expected to move exposure, the reasoning for adjusting the calculated target is written down before the infusion, not reconstructed afterward.

In the Clinical Companion

The app carries the interaction checks and records the reasoning, so the plan and the rationale stay attached to the record.

In how it is described

Graduates are asked not to describe their practice as genetically guided or personalized beyond what the evidence supports. “We review your medications and your history, and we plan the infusion around them” is accurate. “We dose by your genes” is not.

The Clinical Companion and KIRT-S →

Being straight about the evidence

Where the line falls.

What is established

The metabolic pathway, the enzymes that carry it, and the direction and rough size of several specific drug interactions. All of it is published and replicable.

What is not

That genotype should set the dose. That body habitus predicts the concentration. That any measurable patient characteristic reliably tells you where an individual will land.9 Ketamine’s psychiatric use is itself off-label.

Why it is taught anyway

Because knowing which interactions are real — and which are not — changes what a clinician does before an infusion. And because knowing what cannot be predicted is what makes the case for measuring.

How it is described

As pharmacology a clinician should know, not as a service to advertise.

Ketamine is FDA-approved as an anesthetic. Its use for depression, chronic pain and other psychiatric indications is off-label, which means the FDA has not evaluated it for those uses.

Questions

About precision medicine in this program.

Do I need to order pharmacogenomic testing to practice this way?

No. It is not a requirement for an infusion, and it is not ordered routinely here. It is used in complicated cases, and it is used whenever a patient already has a report. Most of what changes a plan comes out of a careful medication history, which costs nothing — but you should be able to read a report and say what it does and does not mean.

A patient brings me a CYP2B6*6 result. What do I do with it?

Note it, expect more variability, and watch that infusion more closely. Do not change the dose on the strength of the genotype alone: the human study that looked for that effect did not find it.

Why do the interaction studies keep using oral ketamine?

Because that is where the effect is largest and easiest to measure. Oral ketamine passes through the liver before it reaches the circulation, so anything that changes hepatic metabolism changes exposure dramatically. Intravenous ketamine bypasses that step, which is why the same interaction is usually smaller — the rifampicin study showed both in one design.

Does this mean a fixed 0.5 mg/kg protocol is wrong?

It means it is a starting point that was never derived from a dose-response study for any single psychiatric indication. Whether a given patient is served by it is an empirical question, answered by watching that patient.

Is any of this FDA-approved?

No. Ketamine is FDA-approved as an anesthetic. Its use in depression, chronic pain and other psychiatric indications is off-label, and nothing on this page changes that.

References

Everything cited on this page.

  1. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002;30(7):853–858.
  2. Li Y, Coller JK, Hutchinson MR, et al. The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro. Drug Metab Dispos. 2013;41(6):1264–1272.
  3. Wang PF, Neiner A, Kharasch ED. Stereoselective ketamine metabolism by genetic variants of cytochrome P450 CYP2B6 and cytochrome P450 oxidoreductase. Anesthesiology. 2018;129(4):756–768.
  4. Rao LK, Flaker AM, Friedel CC, Kharasch ED. Role of cytochrome P4502B6 polymorphisms in ketamine metabolism and clearance. Anesthesiology. 2016;125(6):1103–1112.
  5. Hagelberg NM, Peltoniemi MA, Saari TI, et al. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. Eur J Pain. 2010;14(6):625–629.
  6. Peltoniemi MA, Saari TI, Hagelberg NM, et al. Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clin Pharmacol Ther. 2011;90(2):296–302.
  7. Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT. S-ketamine concentrations are greatly increased by grapefruit juice. Eur J Clin Pharmacol. 2012;68(6):979–986.
  8. Peltoniemi MA, Saari TI, Hagelberg NM, et al. Rifampicin has a profound effect on the pharmacokinetics of oral S-ketamine and less on intravenous S-ketamine. Basic Clin Pharmacol Toxicol. 2012;111(5):325–332.
  9. Kamp J, Olofsen E, Henthorn TK, van Velzen M, Niesters M, Dahan A. Ketamine pharmacokinetics: a systematic review of the literature, meta-analysis and population analysis. Anesthesiology. 2020;133(6):1192–1213.
  10. Highland JN, Farmer CA, Zanos P, et al. Sex-dependent metabolism of ketamine and (2R,6R)-hydroxynorketamine in mice and humans. J Psychopharmacol. 2022;36(2):170–182.
  11. Olofsen E, Noppers I, Niesters M, et al. Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. Anesthesiology. 2012;117(2):353–364.
  12. Zarate CA Jr, Brutsche N, Laje G, et al. Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry. 2012;72(4):331–338. (See the 2016 published erratum.)
  13. Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533(7604):481–486.
  14. Fanta S, Kinnunen M, Backman JT, Kalso E. Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. Eur J Clin Pharmacol. 2015;71(4):441–447.
  15. Andrade C. Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry. 2017;78(7):e852–e857.

The full reading library →

This is one afternoon of fifteen modules

The pharmacology sits inside a four-day course and a year of case consultation that follows it.